Filing Details

Accession Number:
0001209191-19-047723
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-29 16:59:51
Reporting Period:
2019-08-27
Accepted Time:
2019-08-29 16:59:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1108109 Community Health Systems Inc CYH () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1018660 T Wayne Smith 4000 Meridian Boulevard
Franklin TN 37067
Chairman & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-27 495,600 $1.84 3,132,082 No 4 P Direct
Common Stock Acquisiton 2019-08-28 489,250 $2.05 3,621,332 No 4 P Direct
Common Stock Acquisiton 2019-08-29 215,150 $2.18 3,836,482 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 206,842 Indirect by 2009 WTS Irrevocable Trust Dated 2/27/09
Common Stock 481,721 Indirect WAC LLC
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (Right to Buy) $30.32 2011-02-24 2020-02-23 50,000 50,000 Direct
Common Stock Stock Options (Right to Buy) $34.38 2012-02-23 2021-02-22 50,000 50,000 Direct
Common Stock Stock Options (Right to Buy) $17.49 2013-02-16 2022-02-15 40,000 40,000 Direct
Common Stock Stock Options (Right to Buy) $4.99 2020-03-01 2029-02-28 78,750 78,750 Direct
Common Stock Performance Based Restricted $0.00 75,000 75,000 Direct
Common Stock Performance Based Restricted $0.00 105,000 105,000 Direct
Common Stock Performance Based Restricted $0.00 157,500 157,500 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2020-02-23 50,000 50,000 Direct
2021-02-22 50,000 50,000 Direct
2022-02-15 40,000 40,000 Direct
2029-02-28 78,750 78,750 Direct
75,000 75,000 Direct
105,000 105,000 Direct
157,500 157,500 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on 8/27/2019 at prices ranging from $1.80 to $1.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1), (2) and (3) of this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on 8/28/2019 at prices ranging from $1.87 to $2.14, inclusive.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on 8/29/2019 at prices ranging from $2.12 to $2.20, inclusive.
  4. The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2017 and 12/31/2019 (the "2017-2019 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2017-2019 Performance Period.
  5. The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2018 and 12/31/2020 (the "2018-2020 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2018-2020 Performance Period.
  6. The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2019 and 12/31/2021 (the "2019-2021 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2019-2021 Performance Period.